Вернуться к содержанию
«Вестник анестезиологии и реаниматологии» Том 14, №4, 2017,

DOI : 10.21292/2078-5658-2017-14-4-61-71

Опиоидные анальгетики в терапии болевых синдромов (часть 2)

Д. М. Арбух 1 , Г. Р. Абузарова 2 , Г. С. Алексеева 3

  • 1 Клиника боли «Индиана», Индианаполис, США
  • 2 Центр паллиативной помощи онкологическим больным, Москва, Россия
  • 3 ФГБУ «НМИРЦ» МЗ РФ, Москва, Россия

Обзор продолжает информирование читателей о современных опиоидных препаратах, начатое в предыдущем номере. Учитывая возросший интерес к терапии боли опиоидными препаратами в последние годы, публикация будет полезна для широкого круга врачей, занимающихся лечением острой и хронической боли.

Ключевые слова: опиоидные анальгетики, история создания, фармакология, фармакокинетика опиоидов, сравнительная эффективность опиоидных препаратов, комбинации опиоидных препаратов

Литература

  • 1. Adams M. P., Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets // Drugs R D. − 2005. – Vol. 6, № 2. – P. 91–99.
  • 2. Arbuck D. Management of opioid tolerability and adverse effects // J. Medicine. − 2010. – Vol. 3, № 1. – P. 1−10.
  • 3. Barsotti C. E., Mycyk M. B., Reyes J. Withdrawal syndrome from tramadol hydrochloride // Am. J. Emerg. Med. − 2003. – Vol. 21, № 1. – P. 87–88.
  • 4. Baselt R. Disposition of toxic drugs and chemicals in man (8 edition.) // Foster City, CA: Biomedical Publications. − 2008. − P. 911−914.
  • 5. Bodkin J. A., Zornberg G. L., Lukas S. E. et al. Buprenorphine treatment of refractory depression // J. Clin. Psychopharmacology. − 1995. – Vol. 15, № 1. – P. 49–57.
  • 6. Bolan E. A., Tallarida R. J., Pasternak G. W. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes // J. Pharmacol. Exp. Ther. − 2002. – Vol. 303. – P. 557–562.
  • 7. Brody J. A. Mix of medicines that can be lethal // New York Times, Feb 27, 2007. P. F7 "The death of Libby Zion, an 18-year-old college student, in a New York hospital on March 5, 1984, led to a highly publicized court battle and created a cause célèbre over the lack of supervision of inexperienced and overworked young doctors. But only much later did experts zero in on the preventable disorder that apparently led to Ms. Zion’s death: a form of drug poisoning called serotonin syndrome."
  • 8. Brunton L. Goodman & Gilman's pharmacological basis of therapeutics (12th ed.). McGraw-Hill. − 2010. − P. 549.
  • 9. Ciccozzi A., Angeletti C. et al. High dose of buprenorphine in terminally ill patient with liver failure // J. Opioid Manag. − 2012. – Vol. 8, № 4. – P. 253−259.
  • 10. Daniels S., Upmalis D., Okamoto A. et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain // Cur. Med. Res. Opin. − 2009. – Vol. 25, № 3. – P. 765–776 https://www.ncbi.nlm.nih.gov/pubmed/19203298
  • 11. Davis M. P. Buprenorphine in cancer pain // Support Care Cancer. − 2005. – Vol. 13. – P. 878−887.
  • 12. Davis M. P. Opioids for cancer pain. (2 edition.) // Oxford UK: Oxford University Press. − 2009. − 487 p.
  • 13. Davis M. P. Use of pethidine for pain management in the emergency department: a position statement of the NSW Therapeutic Advisory Group // New South Wales Therapeutic Advisory Group., Retrieved 2007−01−17.
  • 14. Dean L. Tramadol Therapy and CYP2D6 Genotype, Medical Genetics Summaries, September 10, 2015. https://www.ncbi.nlm.nih.gov/books/NBK315950/
  • 15. Grond S., Sablotzki A. Clinical pharmacology of tramadol. La de la de da // Clin. Pharmacokinetics. − 2004. – Vol. 43, № 13. – P. 879–923.
  • 16. Hara K., Minami K., Sata T. The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes // Anesthesia and Analgesia. − 2005. – Vol. 100, № 5. – P. 1400–1405.
  • 17. Hopwood S. E., Owesson C. A., Callado L. F. et al. Effects of chronic tramadol on pre- and post-synaptic measures of mono-amine function // J. Psycho-рharmacology. − 2001. – Vol. 15, № 3. – P. 147–153.
  • 18. http://www.tramadolinfo.com/articles/history.html
  • 19. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm518697.htm
  • 20. Huang P., Kehner G. B. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist // J. Pharmacol. Exp. Ther. − 2001. – Vol. 297, № 2. – P. 688–695.
  • 21. Hutson P. R., Williams K. J. Methadone, buprenorphine and levorphanol: alternatives for treatment of chronic pain a comparison of the unique properties of each drug and clinical advantages and disadvantages of their use // JPSW. 2009; January/February https://www.mypcnow.org/blank-s5bm4
  • 22. International Narcotics Control Board Report 2008. United Nations Pubns. − 2009. − P. 20.
  • 23. Izenwasser S., Amy H. N., Brian M. C. et al. The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter // Eur. J. Pharmacology (Elsevier). – Vol. 297, № 1–2. – P. 9–17.
  • 24. Kalso E. Oxycodone // J. Pain Symptom Management. − 2005. – Vol. 29 (5S). – P. 47–56.
  • 25. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? // Curr. Rheumatol. Rep. − 2008. – Vol. 10, № 1. – P. 11−18.
  • 26. Katz. N. et al. Challenges in the development of prescription opioid abuse-deterrent formulations // Clin. J. Pain. − 2007. – Vol. 23, № 8. – P. 648−660.
  • 27. Kenneth L. S., Ginsberg B., Barkin R. L. Meperidine: a critical review // American Journal of Therapeutics (Lippincott Williams & Wilkins). January/February. − 2002. – Vol. 9, № 1. – P. 53–68.
  • 28. Labate A., Newton M. R. Tramadol and new-onset seizures [letter] // Med. J. Australia. − 2005. – Vol. 182, № 1. – P. 42–43.
  • 29. Lalovic B., Kharasch E. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites // Clin. Pharmacol. Ther. − 2006. – Vol. 79. – P. 461–479.
  • 30. Likar R. Transdermal buprenorphine in the management of persistent pain − safety aspects // Therap. Clin. Risk Management. − 2006. – Vol. 2, № 1. – P. 115–125.
  • 31. Max M. B., Payne R. Principles of analgesic use in the treatment of acute pain and chronic cancer pain // Clin. Pharm. − 1990. – Vol. 9, № 8. – P. 601−612.
  • 32. McNulty J. Can levorphanol be used like methadone for intractable refractory pain? // J. Pall Med. − 2007. – Vol. 10, № 2. – P. 293−296.
  • 33. Mintzer I. L., Eisenberg M., Terra M. et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings // Ann. Fam. Med. − 2007. – Vol. 5, № 2. – P. 146–150.
  • 34. Modified from pain physician. − 2011; 14: E343−360 This is a document from the site www.dolor.org.co
  • 35. Moody D. E., Fang W. B., Lin S.-N. et al. Effect of Rifampin and Nelfinavir on the Metabolism of Methadone and Buprenorphine in Primary Cultures of Human Hepatocytes // Drug. Metabol. Disposition. − 2009. − Vol. 37, № 12. − Р. 2323–2329.
  • 36. Pergolizzi J., Böger R. H., Budd K. et al. Consensus statement. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone) // Pain. Practice. − 2008. − Vol. 8, Iss. 4. − Р. 287–313.
  • 37. Pergolizzi J., Aloisi A. M. et al. Current knowledge of buprenorphine and its unique pharmacological profile // Pain. Practice. − 2010. − Vol. 10, № 5. − Р. 428–450.
  • 38. Pert C. B., Snyder S. H. Opiate receptor: demonstration in nervous tissue // Science, 1973, March, 179 (4077). − Р. 1011–1014.
  • 39. Prommer E. Levorphanol: the forgotten opioid // Support Care Cancer. − 2007. − Vol. 15, № 3. − Р. 259−264.
  • 40. Questions and answers on the withdrawal of the marketing authorisations for medicines containing dextropropoxyphene // Europ. Med. Agency. − 25 June 2009.
  • 41. Riesma R., Forbes C. et al. Systematic review of tapentadol in chronic severe pain // Curr. Med. Res. Opin. − 2011. − Vol. 27, № 10. − Р. 1907−1930.
  • 42. Ross F. B., Smith M. T. The intrinsic antinocieptive effects of oxycodone appear to be kappa-opioid receptor mediated // Pain. − 1997. − Vol. 73. − Р. 151−157.
  • 43. Rowbotham M. C., Twilling L. et al. Oral opioid therapy for Chronic Peripheral and Central Neuropathic Pain // N. Engl. J. Med. − 2003. − Vol. 348. − Р. 1223–1232.
  • 44. Sinatra R. The Essence of Analgesia and Analgesics. MA, USA: Cambridge University Press; 2010. 1 edition. p. 123
  • 45. Sloan P. A., Barkin P. I. Oxymorphone and oxymorphone extended release: A pharmacotherapeutic review // J. Opioid Manag. − 2008. − Vol. 4. − Р. 3131−3144.
  • 46. Sneader W. Drug discovery: a history // Hoboken, NJ: Wiley. − 2005. − P. 119.
  • 47. Still R. Transdermal buprenorphine in cancer pain and palliative care // Palliat. Med. − 2006. − Vol. 20, Suppl. 1. − Р s25−s30.
  • 48. Terlinden R., Ossig, J., Fliegert F. et al. Pharmacokinetics, Excretion and Metabolism of Tapentadol HCl, a Novel Centrally Acting Analgesic in Healthy Subjects. Program and Abstracts of the 25th Annual Scientific Meeting of the American Pain Society. May 3–6, 2006 San Antonio, Texas. Poster 689.
  • 49. Thomas J. M., Hoffman B. B. Buprenorphine prevents and reverses the expression of chronic endorphine-induced sensitization of adenylyl cyclase in SK−N−SH human neuroblastoma cells // J. Pharmacol. Exp. Ther. − 1993. − Vol. 264, № 1. − Р. 368−374.
  • 50. Tiwari S. B., Rajabi-Siahboomi A. R. Drug Delivery Systems Methods in Molecular Biology™ Vol. 437. − P. 217−244.
  • 51. Trescot A., Datta S. еt al. Opioid pharmacology // Pain Physician. − 2008. − Opioid Special Issue: 11. − Р. S133−S153.
  • 52. Tzschentke T. M., Christoph T., Kögel, B. еt al. (−)−(1R,2R)−3−(3−Dimethylamino−1−ethyl−2−methyl−propyl)−phenol Hydrochloride (Tapentadol HCl): A Novel μ−Opioid Receptor Agonist / Norepinephrine Reuptake Inhibitor with Broad−Spectrum Analgesic Properties // J. Pharmacol. Experim. Therapeutics. − 2007. − Vol. 323, № 1. − Р. 265–276.
  • 53. U.S. Department of Health and Human Services Food and Drug Administration
Center for Drug Evaluation and Research (CDER). Guidance for Industry. Abuse−Deterrent Opioids — Evaluation and Labeling, April, 2015: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf
  • 54. Volpe D. A., Tobin G. A. M. et al. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs // Regulat. Toxicol. Pharmacol. − 2011. − Vol. 59, № 3. − Р. 385–390.
  • 55. Weinberg D. S., Inturrisi C. E., Reidenberg B. et al. Sublingual absorption of selected opioid analgesics // Clin. Pharmacol. Therapeutics. − 1988. − Vol. 44, № 3. − Р. 335–342.
  • 56. Wise D. Handbook of Pharmaceutical Control Release Technology // Marcel Dekker, Inc., 2000.
  • 57. Yassen A., Kan J., Olofsen E. et al. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats // J. Pharmacol. Experimental Therapeutics. − 2007. − Vol. 321, № 2. − Р. 598–607.
  • 58. Zajac A. (November 19, 2010). "Darvon, Darvocet painkillers pulled from the U.S. market". Los Angeles Times
  • 59. http://www.cnn.com/2010/HEALTH/11/19/fda.removes.drug/

Для цитирования: Арбух Д. М., Абузарова Г. Р., Алексеева Г. С. Опиоидные анальгетики в терапии болевых синдромов (часть 2) «Вестник анестезиологии и реаниматологии» 2017; 14(4):61-71. DOI : 10.21292/2078-5658-2017-14-4-61-71


Для цитирования: Арбух Д. М., Абузарова Г. Р., Алексеева Г. С. Опиоидные анальгетики в терапии болевых синдромов (часть 2) «Вестник анестезиологии и реаниматологии» 2017; 14(4):61-71. DOI : 10.21292/2078-5658-2017-14-4-61-71

Для доступа нужна подписка. Войдите в систему для подтверждения ее наличия.